BiologIC Technologies’ Post

🎥 SPOTLIGHT CLIP: As the field of #biotechnology forges a new wave of genetic medicines, developments in science and technology are widening access to effective and efficient Car T-cell therapies. 🔬 CAR T-cell therapy is a #cancer #immunotherapy treatment that involves genetically modifying a patient's T cells to recognize and destroy cancer cells. ⚕️⚕️ We’re spotlighting Kelonia Therapeutics and its next generation gene delivery platform -- #technology that 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐬 𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐢𝐧𝐬𝐭𝐫𝐮𝐜𝐭𝐢𝐨𝐧𝐬 𝐝𝐢𝐫𝐞𝐜𝐭𝐥𝐲 𝐚𝐧𝐝 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜𝐚𝐥𝐥𝐲 𝐭𝐨 𝐭𝐡𝐞 𝐝𝐞𝐬𝐢𝐫𝐞𝐝 𝐜𝐞𝐥𝐥𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐩𝐚𝐭𝐢𝐞𝐧𝐭’𝐬 𝐢𝐦𝐦𝐮𝐧𝐞 𝐬𝐲𝐬𝐭𝐞𝐦. 🩻 This enables a “reeducation” of a patient’s white blood cells, without the need for pre-treatment with chemotherapies. 💉 The tech overcomes central challenges across existing therapies, such as lengthy and costly #manufacturing. “𝙏𝙝𝙚 𝙘𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚 𝙬𝙞𝙩𝙝 𝙘𝙪𝙧𝙧𝙚𝙣𝙩 𝘾𝘼𝙍 𝙏 𝙘𝙚𝙡𝙡 𝙢𝙚𝙙𝙞𝙘𝙞𝙣𝙚𝙨 𝙞𝙨 𝙩𝙝𝙖𝙩 𝙩𝙝𝙚𝙮 𝙖𝙧𝙚 𝙢𝙖𝙣𝙪𝙛𝙖𝙘𝙩𝙪𝙧𝙚𝙙 '𝙥𝙚𝙧𝙨𝙤𝙣𝙖𝙡' 𝙛𝙤𝙧 𝙚𝙫𝙚𝙧𝙮 𝙥𝙖𝙩𝙞𝙚𝙣𝙩. 𝙆𝙚𝙡𝙤𝙣𝙞𝙖 𝙞𝙨 𝙤𝙫𝙚𝙧𝙘𝙤𝙢𝙞𝙣𝙜 𝙩𝙝𝙚𝙨𝙚 𝙘𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚𝙨 𝙗𝙮 𝙧𝙚𝙙𝙪𝙘𝙞𝙣𝙜 𝙩𝙝𝙚 𝙘𝙤𝙨𝙩, 𝙖𝙣𝙙 𝙗𝙮 𝙢𝙖𝙠𝙞𝙣𝙜 𝙩𝙝𝙚𝙢 𝙡𝙚𝙨𝙨 𝙥𝙚𝙧𝙨𝙤𝙣𝙖𝙡 𝙖𝙣𝙙 𝙢𝙤𝙧𝙚 𝙗𝙧𝙤𝙖𝙙𝙡𝙮 𝙖𝙘𝙘𝙚𝙨𝙨𝙞𝙗𝙡𝙚. 𝙏𝙝𝙚 𝙪𝙣𝙞𝙦𝙪𝙚 𝙣𝙖𝙩𝙪𝙧𝙚 𝙤𝙛 𝙤𝙪𝙧 𝙞𝙂𝙋𝙎 (𝙞𝙣 𝙫𝙞𝙫𝙤 𝙂𝙚𝙣𝙚 𝙋𝙡𝙖𝙘𝙚𝙢𝙚𝙣𝙩 𝙎𝙮𝙨𝙩𝙚𝙢) 𝙥𝙖𝙧𝙩𝙞𝙘𝙡𝙚𝙨 𝙞𝙨 𝙩𝙝𝙖𝙩 𝙬𝙚 𝙘𝙖𝙣 𝙙𝙤 𝙩𝙝𝙞𝙨 𝙬𝙞𝙩𝙝 𝙥𝙤𝙩𝙚𝙣𝙩𝙞𝙖𝙡𝙡𝙮 𝙖𝙣 𝙚𝙭𝙘𝙚𝙥𝙩𝙞𝙤𝙣𝙖𝙡𝙡𝙮 𝙡𝙤𝙬 𝙙𝙤𝙨𝙚 𝙡𝙚𝙫𝙚𝙡, 𝙬𝙝𝙚𝙧𝙚 𝙬𝙚 𝙤𝙣𝙡𝙮 𝙢𝙤𝙙𝙞𝙛𝙮 𝙩𝙝𝙚 𝙘𝙚𝙡𝙡𝙨 𝙩𝙝𝙖𝙩 𝙬𝙚 𝙬𝙖𝙣𝙩.” Watch these short snippets from our recent segment with Kelonia CEO & Co-Founder Kevin Friedman; Kelonia's Director of Preclinical Research Emily Thompson Beura, PhD; Director of the Center for Multiple Myeloma at Mass General Hospital and Professor of Medicine at Harvard Medical School, Noopur Raje; and Professor of Biological Engineering at Massachusetts Institute of Technology, Michael Birnbaum. #biotech #pharma #science #innovation #medicine #education #health 🎬 𝗗𝗠𝗚 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻𝘀

𝐂𝐞𝐥𝐥 𝐂𝐮𝐥𝐭𝐮𝐫𝐞 𝐢𝐧 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 🔬 📌𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅𝐬 𝐚𝐭: https://lnkd.in/dMrpsdRV (𝙐𝙨𝙚 𝘾𝙤𝙧𝙥𝙤𝙧𝙖𝙩𝙚 𝙈𝙖𝙞𝙡 𝙄𝙙 𝙛𝙤𝙧 𝙌𝙪𝙞𝙘𝙠 𝙍𝙚𝙨𝙥𝙤𝙣𝙨𝙚) Cell culture plays a pivotal role in biotechnology, pharmaceuticals, and medical research. By growing cells in a controlled environment, we can simulate in vivo conditions, enabling researchers to study cellular behaviors, test new drugs, and develop groundbreaking therapies. Whether it's cancer research, vaccine development, or stem cell therapy, the ability to culture cells has accelerated scientific advancements in ways once thought impossible. 🌱✨ 🔍 𝐊𝐞𝐲 𝐛𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐨𝐟 𝐜𝐞𝐥𝐥 𝐜𝐮𝐥𝐭𝐮𝐫𝐞: ✅ Drug discovery & testing ✅ Vaccine development ✅ Personalized medicine ✅ Understanding cellular processes As technology continues to evolve, so does our understanding of cell biology. The future of medical treatments and innovations is rooted in the potential of cell culture. 🔍 𝐊𝐞𝐲 𝐓𝐫𝐞𝐧𝐝𝐬: ✅ Increasing demand for 𝟑𝐃 𝐜𝐞𝐥𝐥 𝐜𝐮𝐥𝐭𝐮𝐫𝐞𝐬 for more accurate disease modeling. ✅ Integration with 𝐛𝐢𝐨𝐩𝐫𝐢𝐧𝐭𝐢𝐧𝐠 for creating functional tissues and organs. ✅ Use in 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 and personalized medicine research. 📌𝐒𝐨𝐮𝐫𝐜𝐞: @mrbiyolog 📌𝐃𝐢𝐬𝐜𝐥𝐚𝐢𝐦𝐞𝐫: I don't intend any copyright (DM me for credit & removal) #CellCulture #Biotechnology #MedicalResearch #Innovation #DrugDiscovery #StemCellResearch #Pharmaceuticals #LifeSciences

The Federal Economic Development Agency for Southern Ontario (FedDev Ontario) is providing a total of $8.75 million to three Ottawa-based life sciences companies. The funding includes $1.5 million investment to Virica Biotech Inc., to support and scale new advanced manufacturing of its viral sensitizers at its expanded facility at Carleton University. Virica Biotech pioneered a new viral sensitizer that boosts the efficacy of using viruses to help treat cancer, removing the barriers to manufacturing effective viral medicines at scale. FedDev Ontario also is providing $1.75 million to Genvira Biosciences Inc., which builds innovative biotherapeutics, examining how human cells change and mutate to help create vaccines, supporting advancements in gene therapy and cancer immunotherapy. The funding will help the company enhance its biomaterials manufacturing capabilities, to better serve clinicians as they undertake clinical trials. FedDev Ontario’s third investment is $5.5 million in Capital Bioventures, a not-for-profit wet-lab accelerator that provides Canadian biotech companies with early-stage funding and access to dedicated drug and corporate development biotech professionals, and access to high-quality equipment and lab space. The organization is addressing the critical need for wet lab space in the region, by establishing and launching an Ottawa-based wet-lab accelerator program that will allow SMEs to utilize wet lab space in locations across the city. #FedDevOntario #LifeSciencesFunding #OttawaBiotech #ViricaBiotech #CancerTreatment #AdvancedManufacturing #GenviraBiosciences #GeneTherapy #CancerImmunotherapy #CapitalBioventures #WetLabAccelerator #BiotechInnovation #EconomicDevelopment #HealthcareResearch #BiotechFunding

🔬🧬 𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐁𝐞𝐭𝐚-𝐂𝐚𝐭𝐞𝐧𝐢𝐧 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐚𝐧𝐝 𝐓𝐫𝐞𝐧𝐝𝐬 🌟💼 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gM8S9pcV The beta-catenin antibody market comprises products used in biomedical research and clinical diagnostics to detect and analyze the presence of beta-catenin protein in cells and tissues. Beta-catenin is a key protein involved in various cellular processes, including cell adhesion, signal transduction, and gene expression regulation. Dysregulation of beta-catenin signaling pathways has been implicated in various diseases, including cancer and developmental disorders. Key components of the beta-catenin antibody market include monoclonal and polyclonal antibodies specific to beta-catenin, as well as assay kits, reagents, and instruments for immunohistochemistry, western blotting, flow cytometry, and other techniques used to detect and quantify beta-catenin expression levels. #Company Sino Biological, Inc. Boster Biological Technology Bio-Techne Thermo Fisher Scientific Cloud-Clone Corp MyBioSource Wuhan Fine Biotech Co., Ltd. Abbexa ZellBio GmbH Biomatik Corporation Assay Genie Creative Diagnostics RayBiotech Cusabio Technology LLC Cepham Life Sciences, Inc. #Type Monoclonal Antibody Polyclonal Antibody #Application Flow Cytometry ELISA Western Blot Immunoprecipitation Immunofluorescence Other #follow Stringent Datalytics - Healthcare #BetaCateninAntibody #Marketresearch #researchreport #healthcareindustry #marketgrowth #healthcare

AI enables the targeted design of novel therapeutic modalities. In the dynamic world of drug discovery, companies must continually innovate beyond their existing drug portfolios and modalities. Relying solely on familiar modalities limits the potential to develop more effective treatments. The industry now explores a variety of therapeutic strategies, from established monoclonal antibodies (mAbs) and RNA therapies to cutting-edge gene editing and cell therapies like CRISPR and CAR-T. Additionally, the small molecule space is evolving with technologies like PROteolysis TArgeting Chimeras (PROTACs), targeted protein degraders (TPDs), covalent inhibitors, and macrocycles, which target complex molecular structures previously deemed 'undruggable.' These advances, including the potential for synergistic combinations of these modalities, underscore the necessity for continuous innovation in drug discovery, integrating new and established technologies to develop groundbreaking treatments. Here is a great report by Revvity Signals, The Innovation Imperative: Pioneering New Modalities for Therapeutic Leadership, which provides a bird's-eye view of the trends in the space of novel modalities: In the latest newsletter (link in the comments), we reviewed four biotech startups developing AI platform-based approaches to design novel breakthrough modalities. #drugdiscovery #biotech #biopharmatrend Image credit: Revvity Signals

🚀 #DeliveringScience: Exploring Oligonucleotide-Based Therapies At Certest Pharma, we're passionate about advancing biotechnological innovations. Oligonucleotide-based therapies are at the forefront of modern medicine, offering precise and targeted treatments for various genetic disorders. Let's delve into the different types: 🔹Antisense Oligonucleotides (ASOs): These bind to RNA molecules to modulate gene expression, offering therapeutic potential in conditions like spinal muscular atrophy. 🔹Small Interfering RNAs (siRNAs): siRNAs degrade specific mRNA molecules, effectively silencing genes involved in diseases like cancer and viral infections. 🔹Aptamers: Aptamers are short, single-stranded DNA or RNA molecules that bind to specific targets, such as proteins, with high affinity, serving as excellent therapeutic and diagnostic tools. 🔹Locked Nucleic Acids (LNAs): LNAs enhance the stability and binding affinity of oligonucleotides, improving their efficacy and safety in gene silencing applications. The advantages of these therapies include high specificity, the ability to target previously "undruggable" genes, and a relatively rapid development timeline compared to traditional small-molecule drugs. As we continue to innovate and improve these technologies, we move closer to tailored treatments that can change lives. 💡Stay tuned for more updates from Certest Pharma as we push the boundaries of science! #CertestPharma #Oligonucleotides #Biotech #GeneTherapy #Innovation

5 key considerations to design in vitro assays for ASO screening 💡 With newly developed antisense oligonucleotide (ASO) molecules, early efficacy and toxicity assessment is crucial to prevent costly failures in later stages. But, what are the assays that will give you the best predictions to advance your drug candidate with confidence? Don't ignore these 5 tips: 🔶 Choose a cell model that's relevant to your target disease Induced pluripotent stem cells (iPSCs) offer the physiological relevance of primary cells while also having the unlimited proliferative capacity of immortalized lines. 🔶 Make sure the readout technology is relevant too Common examples included PCR-based methods and high-content imaging. 🔶 Understand the expression profile of your target gene Cellular models need to be cultured under physiological conditions and the kinetics of the target gene established. 🔶 Select the right method for ASO delivery Depending on the properties of the ASO molecules, as well as the target cell and its membrane permeability, passive diffusion might be sufficient, or you might need transfection reagents or nucleofection. 🔶 Optimize assay conditions The screening protocol is further optimized to maximize sensitivity, specificity, and reproducibility by determining the appropriate oligonucleotide concentrations, duration of the ASO exposure, overall assay conditions. Want more detailed advice? Read the full blog with the link in the comments ⬇ Or send a message to discuss your project! #biotechnology #drugdiscovery #research

Future of Medicine: Growth in the mRNA Synthesis & Manufacturing Market! 🧬 📥 Download the PDF: https://lnkd.in/dW4U4EiJ The mRNA synthesis and manufacturing market is set to expand from USD 2,231.4 million in 2024 to USD 2,958.3 million by 2029 at a 5.8% CAGR. This growth is driven by advancements in gene and cell therapies (CGT), vaccines, and cutting-edge solutions across transcription, purification, and characterization processes. With rising demand, manufacturing and scale-up services are also accelerating, paving the way for more accessible and efficient healthcare solutions. 🌍🔬 From consumables to instruments and services, innovation in this field will redefine what’s possible in precision medicine and beyond. 💡 Are you or your organization working with mRNA tech? Let’s connect and shape the future of healthcare together! #mRNA #BiotechInnovation #HealthcareTransformation #CGT #Vaccines #PrecisionMedicine #LinkedInInnovation

With 10 years in biotech, I specialize in iPSCs for drug discovery. I do so because commonly used immortalized lines and animal models are often not therapeutically relevant enough to 𝗰𝗼𝗻𝗳𝗶𝗱𝗲𝗻𝘁𝗹𝘆 𝗽𝗿𝗲𝗱𝗶𝗰𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀, resulting in failed clinical trials despite enormous time and money. Thus, to bridge this translational gap, Ncardia incorporates 𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝘁 𝗵𝘂𝗺𝗮𝗻 𝗯𝗶𝗼𝗹𝗼𝗴𝘆 in drug discovery by: 🔶 starting with specified donor tissue 🔶 reprogramming into induced pluripotent stem cells (iPSCs) 🔶 creating or fixing mutations with CRISPR, if needed 🔶 differentiating into cell types of interest 🔶 scaling up production, depending on required cell numbers 🔶 using these iPSC-derived cells for modeling, screening, efficacy, and safety/toxicity Such an approach 𝗿𝗲𝘃𝗲𝗮𝗹𝘀 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗼𝗳𝘁𝗲𝗻 𝗺𝗶𝘀𝘀𝗲𝗱 by other models. Beyond iPSCs in drug discovery, Ncardia also has expertise in process development and manufacturing of 𝗶𝗣𝗦𝗖-𝗱𝗲𝗿𝗶𝘃𝗲𝗱 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 through its sister company Cellistic. Curious? Let's 𝘀𝗲𝘁 𝘂𝗽 𝗮 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 to discuss your drug discovery or cell therapy program. #drugdiscovery #celltherapy #biotechnology

#TechnoteTuesday The rise of lentiviral vectors (LVVs) in gene and cell therapy marks a significant leap forward in medical science. Yet, the complexity of these vectors and the limited analytical methods available create formidable challenges in clinical development. For those of us at the forefront of this field, the need for precise, efficient tools to navigate these challenges is paramount. That’s where multi-capillary electrophoresis-based workflows come into play. These advanced workflows simplify the critical tasks of characterizing LVVs and evaluating in-process attributes. They provide detailed protein profiles and accurate p24-based titer measurements on the proteomic front. Genomically, they assess genome integrity and detect residual nucleic acids—both essential for ensuring the efficacy and safety of your therapeutic products. The stakes are high, with over 89% of cell and gene therapies in development relying on viral vectors. LVVs, with their ability to stably integrate genetic material and deliver large sequences, have become a cornerstone in pre-clinical development. But the precision in their characterization will ultimately determine their success. This technical note showcases how capillary electrophoresis (CE) is transforming the way we approach LVV analysis, offering a platform-based solution that addresses the technical hurdles head-on. By embracing these innovative methods, we can better ensure the safety and effectiveness of the therapies that have the potential to change lives. This week, Aaron Shafer, Alicia Powers, @Yan Lu, chao-xuan zhang, Timothy Lockey, Catherine Willis, @Michael Meagher, St. Jude Children's Research Hospital, Tingting Li, Jane Luo, Mario A Pulido, and Sahana Mollah SCIEX, USA teams look at the "Fast Glycan Sequencing Using a Fully Automated Carbohydrate Sequencer." #TechnoteTuesday #development #sciex #BioPhase8800 #CESIMS #SciexforScience #genetherapy #rnatherapeutics #FastGlycan #BioPhase8800 #RNA9000 #mabs #development #sciex #CapillaryElectrophoresis #SciexforScience #genetherapy #rnatherapeutics #PA800Plus #GenomeLabGeXP #immunotherapy #clinicaltrials #safety #biopharmaceuticals